AbbVie: Q4 2024 Earnings Preview And Update On Emraclidine

Company Performance and Guidance - AbbVie (NYSE: ABBV) is set to report Q4 2024 results next week and will provide guidance for 2025 [2] - The company is managing the erosion of Humira effectively, but the decline in Humira's net sales remains a key factor to watch [2] Investment Platform Features - The Growth Stock Forum offers a model portfolio of 15-20 names updated regularly [2] - It includes a top picks list of up to 10 stocks expected to perform well in the current calendar year [2] - The platform provides trading ideas targeting both short-term and medium-term moves [2] - It features community dialogue and a space for questions [2]